Supported by an educational grant from Actelion Pharmaceuticals US, Inc.
Mycosis fungoides (MF) is a rare, cutaneous T-cell lymphoma (MF-CTCL) which presents life-long management challenges. Although the prognosis for advanced disease is poor, for the majority of patients who present with early-stage disease, a number of efficacious treatment options are available. However, early-stage MF-CTCL still provides a significant challenge for clinicians. Due to the rare nature of this disease, clinicians are often not familiar with the presentation of MF-CTCL and an accurate diagnosis is frequently delayed, as early-stage MF-CTCL mimics a number of common cutaneous diseases.
This educational initiative has been designed for dermatologists, dermatology oncologists, oncologists, dermatology nurses, advanced practitioners, pharmacists, and healthcare providers caring for patients with or suspected to have early-stage MF-CTCL.
Upon completion of this educational activity, participants should be able to:
Describe signs and symptoms that should prompt suspicion of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)
Identify barriers to the accurate diagnosis of MF-CTCL and explain how such barriers may be effectively addressed
Outline an individualized approach to the treatment of early-stage MF-CTCL that includes appropriate use of skin-directed therapies for optimized patient care
Conflict Of Interest Disclosure Policy
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Larisa Geskin, MD, FAAD Associate Professor of Dermatology and Medicine Director Comprehensive Cutaneous Oncology Center Columbia University New York, NY
Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.
AMA PRA Category 1 Credit(s)TM
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Integrity Continuing Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Actelion do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education and Actelion. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
There are no fees for participating and receiving CME credit for this activity. During the period of March 5, 2018 through March 5, 2019, participants must:
Read the learning objectives and faculty disclosures
Complete the pre-test
Study the educational activity
Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or firstname.lastname@example.org.